Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Equity (2021 - 2025)

Historic Return on Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 0.07%.

  • Kiniksa Pharmaceuticals International's Return on Equity rose 2600.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 2600.0%. This contributed to the annual value of 0.1% for FY2024, which is 500.0% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Return on Equity stood at 0.07% for Q3 2025, which was up 2600.0% from 0.01% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Return on Equity peaked at 0.79% during Q2 2023, and registered a low of 0.83% during Q4 2021.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Return on Equity value was 0.07% (recorded in 2025), while the average stood at 0.02%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Return on Equity surged by 15400bps in 2023, and later plummeted by -9800bps in 2024.
  • Kiniksa Pharmaceuticals International's Return on Equity (Quarter) stood at 0.83% in 2021, then soared by 183bps to 0.69% in 2022, then plummeted by -121bps to 0.14% in 2023, then skyrocketed by 31bps to 0.1% in 2024, then surged by 171bps to 0.07% in 2025.
  • Its Return on Equity stands at 0.07% for Q3 2025, versus 0.01% for Q2 2025 and 0.04% for Q1 2025.